GlassScriptPhysician profile
Michele Carey
NPI 1295104867
$3,867.58
in general payments reported to CMS, 2019-2025
17 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $774 · 2023: $1,152 · 2024: $158 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,966 · Food and Beverage: $970 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,966.43 |
| Food and Beverage | $969.69 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $1,411.19 | 2022-2025 | Vasoview Hemopro 2, Vasoview Hemopro 2 |
| Intuitive Surgical, INC. | $1,048.54 | 2023 | Da Vinci Surgical System |
| Abiomed | $648.11 | 2025 | |
| Stryker Corporation | $157.35 | 2025 | Flowtriever |
| Novartis Pharmaceuticals Corporation | $127.00 | 2023-2025 | |
| Abbott Laboratories | $125.64 | 2021 | |
| Maquet Cardiovascular L.L.C. | $109.00 | 2025 | Vasoview Hemopro 2 |
| Pfizer INC. | $39.89 | 2024 | |
| Boston Scientific Corporation | $32.86 | 2025 | Enroute Transcarotid Neuroprotection System |
| Novo Nordisk INC | $32.27 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $23.01 | 2025 | Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $22.51 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.11 | 2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $19.86 | 2023 | Xarelto |
| Kestra Medical Technology Services, INC. | $19.03 | 2025 | Assure Wcd |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $16.75 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $14.46 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.